ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "longitudinal studies"

  • Abstract Number: 2514 • 2012 ACR/ARHP Annual Meeting

    Racial/Ethnic Trends in Incidence and Prevalence of Rheumatoid Arthritis in a Large Multi-Ethnic Managed Care Population

    Aniket A. Kawatkar1, Cecilia Portugal1, Li-Hao Chu2 and Rajan Iyer3, 1Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, 2Department of Research and Evaluation,, Kaiser Permanente Southern California, Pasadena, 3Department of Research and Evaluation,, Kaiser Permanente Southern California, Pasadena, CA

    Background/Purpose: As epidemiologic studies throughout the world have shown significant variations, we sought to characterize racial differences in longitudinal epidemiologic trends of adult rheumatoid arthritis…
  • Abstract Number: 448 • 2012 ACR/ARHP Annual Meeting

    Sustained and Cumulated Response Over Time in Rheumatoid Arthritis Patients Treated with Rituximab After Initial Failure of Anti Tumor Necrosis Factor Agents

    Ioan Ancuta1, Catalin Codreanu2, Ruxandra Ionescu3, Magda Parvu4 and Mihai Bojinca5, 1Internal Medicine, Cantacuzino Hospital, Bucharest, Romania, 2Rheumatology, “Dr. I. Stoia” Center for Rheumatic Diseases, Bucharest, Romania, 3Clinic Hospital "Sf. Maria", Bucharest, Romania, 4Internal Medicine, “N.Gh. Lupu” Clinical Hospital, Bucharest, Romania, 5Internal Medicine, “Dr. I. Cantacuzino” Hospital, Bucharest, Romania

    Background/Purpose: Although anti-TNF therapies moved forward the treatment of rheumatoid arthritis (RA), failure of the first anti-TNF medication is not uncommon. Many times modifying dosage/frequency…
  • Abstract Number: 2490 • 2012 ACR/ARHP Annual Meeting

    Herpes Zoster and Tofacitinib Therapy in Patients with Rheumatoid Arthritis

    K. L. Winthrop1, H. Valdez2, E. Mortensen3, R. Chew4, S. Krishnaswami5, T. Kawabata5 and R. Riese4, 1Division of Infectious Diseases, Oregon Health and Science University, Portland, OR, 2Pfizer Inc., New York, NY, 3Global Medical Affairs, Pfizer Inc., Collegeville, PA, 4Pfizer Inc., Groton, CT, 5Pfizer Inc, Groton, CT

    Background/Purpose: Patients (pts) with RA are at increased risk for herpes zoster (HZ) i.e. ‘shingles'. Tofacitinib, a novel oral Janus kinase inhibitor investigated as a…
  • Abstract Number: 449 • 2012 ACR/ARHP Annual Meeting

    Rituximab After First Anti Tumor Necrosis Factor Failure Is More Efficient with High Impact in Reducing Time and Costs to Achieve Superior Rates of Low Disease Activity and Remission

    Ioan Ancuta1, Catalin Codreanu2, Ruxandra Ionescu3, Magda Parvu4 and Mihai Bojinca1, 1Internal Medicine, “Dr. I. Cantacuzino” Hospital, Bucharest, Romania, 2Rheumatology, “Dr. I. Stoia” Center for Rheumatic Diseases, Bucharest, Romania, 3Internal Medicine, Clinic Hospital Sf. Maria, Bucharest, Romania, 4Internal Medicine, “N.Gh. Lupu” Clinical Hospital, Bucharest, Romania

    Background/Purpose: Significant steps were done in creating new medications for treatment of rheumatoid arthritis (RA). As RA seriously affects the patients’ quality of life, the…
  • Abstract Number: 2469 • 2012 ACR/ARHP Annual Meeting

    A Virtual Knee Joint Replacement Clinical Endpoint Based On Longitudinal Trends and Thresholds in Koos Knee Pain and Function in Osteoarthritis Initiative Participants

    Robert M. Boudreau1, David J. Hunter2, Zhijie Wang3, Frank Roemer4, Felix Eckstein5, Michael J. Hannon3, Ali Guermazi6 and C. Kent Kwoh7, 1Epidemiology, University of Pittsburgh, Pittsburgh, PA, 2Rheumatology, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia, 3Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, 4Radiology, Boston University School of Medicine, Boston, MA, 5Anatomy & Musculoskeletal Research, Paracelsus Medical University, Salzburg, Austria, 6Boston University, Boston, MA, 7School of Medicine, Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Knee joint replacement (KR) is a cost-effective procedure with good long-term outcomes, but has limitations as an endpoint in OA intervention trials. A definition…
  • Abstract Number: 390 • 2012 ACR/ARHP Annual Meeting

    Performance of Criteria for Remission in a Long-Term Observational Study of Patients with Early Rheumatoid Arthritis

    Bjorn Svensson1, Maria LE Andersson2, Sidona-Valentina Bala3, Kristina Forslind4 and Ingiäld Hafström5, 1Section of Rheumatology, Institution of Clinical Science, Lund University, Lund, Sweden, 2R&D Center, Spenshult Hospital, Oskarström, Sweden, 3Department of Health Sciences,, Lund University, Lund, Sweden, 4Department of Medicine, Karolinska Institute, Stockholm, Department of Medicine, Karolinska Institute,, Stockholm, Sweden, 5Unit of Rheumatology, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden

    Background/Purpose: Remission is widely accepted as the goal of treatment in RA and has to be sustained to keep joint damage at a minimum (Smolen…
  • Abstract Number: 2158 • 2012 ACR/ARHP Annual Meeting

    Baseline Folate Related Biomarkers in Serum and erythrocytes Are Not Associated with Methotrexate Response and Adverse Events in Rheumatoid Arthritis

    Maurits C.F.J. De Rotte1, Saskia M.F. Pluijm2, Maja Bulatovic3, Johanna M.W. Hazes4 and Robert De Jonge1, 1Clinical Chemistry, Erasmus Medical Center, Rotterdam, Netherlands, 2Public Health, Erasmus Medical center, Rotterdam, Netherlands, 3Department of Paediatric Immunology, University Medical Centre Utrecht, Netherlands, 4Rheumatology, Erasmus MC, Rotterdam, Netherlands

    Background/Purpose: Methotrexate (MTX) is the most commonly used drug in rheumatoid arthritis (RA). 30% of patients fail to respond to the drug or suffer from…
  • Abstract Number: 232 • 2012 ACR/ARHP Annual Meeting

    The Natural History of Sporadic Inclusion Body Myositis – an Observational Longitudinal Study

    Pedro Machado1, Andrea Cortese1, Jasper Morrow1, Liz Dewar1, Andy Hiscock1, Adrian Miller1, Stefen Brady2, David Hilton-Jones2, Matt Parton1 and Michael G. Hanna1, 1MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, London, United Kingdom, 2Oxford Muscle and Nerve Centre, John Radcliffe Hospital, Oxford, United Kingdom

    Background/Purpose: Our aim was to assess prospectively the clinical features and functional impact of inclusion body myositis (IBM), to identify reliable outcome measures for future…
  • Abstract Number: 2161 • 2012 ACR/ARHP Annual Meeting

    Methotrexate Polyglutamate Concentrations in Erythrocytes Are a Potential Tool for Therapeutic Drug Monitoring of Methotrexate Response in Rheumatoid Arthritis

    Maurits C.F.J. De Rotte1, Ethan den Boer2, Maja Bulatovic3, Saskia M.F. Pluijm4, Johanna M.W. Hazes5 and Robert De Jonge1, 1Clinical Chemistry, Erasmus Medical Center, Rotterdam, Netherlands, 2Clinical Chemistry, Erasmus University Hospital, Rotterdam, Netherlands, 3Department of Paediatric Immunology, University Medical Centre Utrecht, Netherlands, 4Public Health, Erasmus Medical center, Rotterdam, Netherlands, 5Rheumatology, Erasmus MC, Rotterdam, Netherlands

    Background/Purpose: Methotrexate (MTX) is the most commonly used drug in rheumatoid arthritis (RA). 30% of patients fail to respond to the drug or suffer from…
  • Abstract Number: 2134 • 2012 ACR/ARHP Annual Meeting

    The Changed Prognosis of Patients with Early Rheumatoid Arthritis

    Karin Britsemmer1 and Dirkjan van Schaardenburg2, 1Rheumatology, Jan van Breemen Research Institute / Reade, Amsterdam, Netherlands, 2Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands

    The Changed Prognosis of Patients with Early Rheumatoid Arthritis Background/Purpose: The treatment of rheumatoid arthritis (RA) has changed greatly during the past fifteen to twenty…
  • Abstract Number: 2068 • 2012 ACR/ARHP Annual Meeting

    Is There a Difference in Rheumatology Patient Reported Outcomes When Measured At Home Versus the Clinic Setting?

    C.J. Inman1, Frederick Wolfe2 and Kaleb Michaud3, 1Pediatric Administration, University of Utah, Salt Lake City, UT, 2National Data Bank for Rheumatic Diseases, Wichita, KS, 3Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Registries have become a common tool for collecting patient-centered outcome measures. Clinical effectiveness research may be improved if data from multiple registries could be…
  • Abstract Number: 1587 • 2012 ACR/ARHP Annual Meeting

    Despite Low Disease Activity Patients with Poly- and Dermatomyositis Perceive Activity Limitation, Reduced Grip Force and Quality of Life Longitudinally

    Malin Regardt1, Marie-Louise Schult2, Ingrid E. Lundberg3 and Elisabet MB Welin Henriksson4, 1Department of Occupational Therapy, Department of Neurobiology, Care Sciences and Society, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 2Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet., Stockholm, Sweden, 3Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, 4Medicine, Karolinska Institutet Rheum, Stockholm, Sweden

    Background/Purpose: Polymyositis (PM) and dermatomyositis (DM) are characterized by proximal muscle weakness. A recent study has shown that patients with PM and DM have reduced…
  • « Previous Page
  • 1
  • …
  • 15
  • 16
  • 17
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology